CCTE Secures 10 CFR Part 810 License, Advancing US-India Civil Nuclear Cooperation
Notified -
Globe Newswire3-09-2025, 19:12
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00